{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:19:52Z","timestamp":1783171192845,"version":"3.54.6"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.radonc.2026.111550","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:17:18Z","timestamp":1776957438000},"page":"111550","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT)"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-9121","authenticated-orcid":false,"given":"Laurelie R.","family":"Wishart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-0386","authenticated-orcid":false,"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3530-3274","authenticated-orcid":false,"given":"June","family":"Corry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8004-717X","authenticated-orcid":false,"given":"Benjamin J","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-5173","authenticated-orcid":false,"given":"Wayne J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2074-6999","authenticated-orcid":false,"given":"Syeda Farah","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8870-3282","authenticated-orcid":false,"given":"Justin","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro V.","family":"Porceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111550_b0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111550_b0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.radonc.2011.05.036","article-title":"MACH-CH Collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site","volume":"100","author":"Blanchard","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111550_b0015","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111550_b0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ijrobp.2008.05.040","article-title":"Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients","volume":"73","author":"Hitchcock","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111550_b0025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.ijrobp.2007.01.042","article-title":"Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis","volume":"68","author":"Zuur","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111550_b0030","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/lary.24802","article-title":"Long-term hearing loss after chemoradiation in patients with head and neck cancer","volume":"124","author":"Theunissen","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.radonc.2026.111550_b0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00129492-200403000-00015","article-title":"A long-term study on hearing status in patients with nasopharyngeal carcinoma after radiotherapy","volume":"25","author":"Wang","year":"2004","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.radonc.2026.111550_b0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000095818","article-title":"Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer","volume":"11","author":"Zuur","year":"2006","journal-title":"Audiol Neurootol"},{"key":"10.1016\/j.radonc.2026.111550_b0045","first-page":"06157","article-title":"Self-perceived hearing outcomes with radiation and cisplatin or radiation and cetuximab for patients with human papilloma virus (HPV)-positive oropharyngeal cancer-results from NRG oncology RTOG 1016","volume":"S0360\u20133016","author":"Runge","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111550_b0050","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00003446-199012000-00004","article-title":"The hearing handicap inventory for adults: psychometric adequacy and audiometric correlates","volume":"11","author":"Newman","year":"1990","journal-title":"Ear Hear"},{"key":"10.1016\/j.radonc.2026.111550_b0055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00003446-199110000-00009","article-title":"Test-retest reliability of the hearing handicap inventory for adults","volume":"12","author":"Newman","year":"1991","journal-title":"Ear Hear"},{"key":"10.1016\/j.radonc.2026.111550_b0060","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111550_b0065","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1200\/JCO.2015.62.5970","volume":"34","author":"Rosenthal","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111550_b0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111550_b0075","doi-asserted-by":"crossref","unstructured":"Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. De-ESCALaTE HPV Trial Group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019 Jan 5;393(10166):51-60.doi: 10.1016\/S0140-6736(18)32752-1.","DOI":"10.1016\/S0140-6736(18)32752-1"},{"key":"10.1016\/j.radonc.2026.111550_b0080","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - a trans-tasman radiation oncology group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111550_b0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.oraloncology.2018.12.010","article-title":"Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients","volume":"89","author":"Teft","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2026.111550_b0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoto.2019.3550","article-title":"Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer","volume":"146","author":"Schuette","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.radonc.2026.111550_b0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.coc.0000143847.57027.16","article-title":"Contouring the middle and inner ear on radiotherapy planning scans","volume":"28","author":"Pacholke","year":"2005","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111550_b0100","unstructured":"American Speech-Language-Hearing Association (n.d.).Hearing Loss in Adults(Practice Portal). Retrieved April 1, 2026, from\/Practice-Portal\/Clinical-Topics\/Hearing-Loss\/."},{"key":"10.1016\/j.radonc.2026.111550_b0105","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1121\/10.0021339","article-title":"Hearing thresholds for \u201cotologically normal\u201d adults from the National Health and Nutrition Examination surveys 2011-12 and 2015-16","volume":"154","author":"Humes","year":"2023","journal-title":"J Acoust Soc Am"},{"key":"10.1016\/j.radonc.2026.111550_b0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/AUD.0b013e3181a61f16","article-title":"Professionals with hearing loss: maintaining that competitive edge","volume":"30","author":"Tye-Murray","year":"2009","journal-title":"Ear Hear"}],"updated-by":[{"DOI":"10.1016\/j.radonc.2026.111550","type":"removal","label":"Removal","source":"publisher","updated":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000}}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026003890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026003890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:47:36Z","timestamp":1783169256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026003890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"alternative-id":["S0167814026003890"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111550","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensorineural hearing outcomes in HPV-positive oropharyngeal cancer: a secondary analysis of the TROG 12.01 randomized trial (SHOUT)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111550","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111550"}}